JOHNSON and Johnson has
today confirmed its plans to buy
Dutch biotechnology company
Crucell NV for $2.29 billion.
According to reports, J&J is
currently in the process of
“advanced negotiations” with
Crucell - in which it already holds a
17.9% stake following an earlystage
collaboration agreement the
pair entered into last year.
The shareholding deal, which
netted Crucell around €20.67 per
share, also effectively made the
biotech company less attractive to
other suitors including Wyeth, which
in 2009 had also been in negotiations
to buy the company.
The J&J buyout will see Crucell
shares each snapped up at €24.75
(a 20% increase on J&J’s 09 buy up).The above article was sent to subscribers in Pharmacy Daily's issue from 20 Sep 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Sep 10
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FROM 01 May, pharmacists will be able to dispense Verzenio (abemaciclib) through the PBS to treat Australian patients with an invasive form of early breast cancer that is at high risk of recurring after initial treatment.
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.